261 related articles for article (PubMed ID: 32877548)
1. Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities.
Krebs E; Zang X; Enns B; Min JE; Behrends CN; Del Rio C; Dombrowski JC; Feaster DJ; Gebo KA; Marshall BDL; Mehta SH; Metsch LR; Pandya A; Schackman BR; Strathdee SA; Nosyk B;
J Infect Dis; 2020 Sep; 222(Suppl 5):S301-S311. PubMed ID: 32877548
[TBL] [Abstract][Full Text] [Related]
2. Ending the HIV epidemic in the USA: an economic modelling study in six cities.
Nosyk B; Zang X; Krebs E; Enns B; Min JE; Behrends CN; Del Rio C; Dombrowski JC; Feaster DJ; Golden M; Marshall BDL; Mehta SH; Metsch LR; Pandya A; Schackman BR; Shoptaw S; Strathdee SA;
Lancet HIV; 2020 Jul; 7(7):e491-e503. PubMed ID: 32145760
[TBL] [Abstract][Full Text] [Related]
3. Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities.
Quan AML; Mah C; Krebs E; Zang X; Chen S; Althoff K; Armstrong W; Behrends CN; Dombrowski JC; Enns E; Feaster DJ; Gebo KA; Goedel WC; Golden M; Marshall BDL; Mehta SH; Pandya A; Schackman BR; Strathdee SA; Sullivan P; Tookes H; Nosyk B;
Lancet HIV; 2021 Sep; 8(9):e581-e590. PubMed ID: 34370977
[TBL] [Abstract][Full Text] [Related]
4. Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.
Bernard CL; Owens DK; Goldhaber-Fiebert JD; Brandeau ML
PLoS Med; 2017 May; 14(5):e1002312. PubMed ID: 28542184
[TBL] [Abstract][Full Text] [Related]
5. The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities.
Krebs E; Zang X; Enns B; Min JE; Behrends CN; Del Rio C; Dombrowski JC; Feaster DJ; Gebo KA; Golden M; Marshall BDL; Metsch LR; Schackman BR; Shoptaw S; Strathdee SA; Nosyk B;
AIDS; 2020 Mar; 34(3):447-458. PubMed ID: 31794521
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.
Alistar SS; Owens DK; Brandeau ML
PLoS Med; 2011 Mar; 8(3):e1000423. PubMed ID: 21390264
[TBL] [Abstract][Full Text] [Related]
7. Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis.
Bernard CL; Rao IJ; Robison KK; Brandeau ML
PLoS Med; 2020 Oct; 17(10):e1003239. PubMed ID: 33048929
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics.
Alistar SS; Owens DK; Brandeau ML
PLoS One; 2014; 9(1):e86584. PubMed ID: 24489747
[TBL] [Abstract][Full Text] [Related]
9. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of alternative strategies for provision of HIV preexposure prophylaxis for people who inject drugs.
Fu R; Owens DK; Brandeau ML
AIDS; 2018 Mar; 32(5):663-672. PubMed ID: 29334549
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of harm reduction.
Wilson DP; Donald B; Shattock AJ; Wilson D; Fraser-Hurt N
Int J Drug Policy; 2015 Feb; 26 Suppl 1():S5-11. PubMed ID: 25727260
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
[TBL] [Abstract][Full Text] [Related]
13. Development and Calibration of a Dynamic HIV Transmission Model for 6 US Cities.
Zang X; Krebs E; Min JE; Pandya A; Marshall BDL; Schackman BR; Behrends CN; Feaster DJ; Nosyk B;
Med Decis Making; 2020 Jan; 40(1):3-16. PubMed ID: 31865849
[No Abstract] [Full Text] [Related]
14. Are major reductions in new HIV infections possible with people who inject drugs? The case for low dead-space syringes in highly affected countries.
Zule WA; Cross HE; Stover J; Pretorius C
Int J Drug Policy; 2013 Jan; 24(1):1-7. PubMed ID: 22884539
[TBL] [Abstract][Full Text] [Related]
15. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA.
Adamson B; Garrison L; Barnabas RV; Carlson JJ; Kublin J; Dimitrov D
J Int AIDS Soc; 2019 Aug; 22(8):e25373. PubMed ID: 31402591
[TBL] [Abstract][Full Text] [Related]
16. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
Long EF; Stavert RR
J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
[TBL] [Abstract][Full Text] [Related]
17. Prospects for ending the HIV epidemic among persons who inject drugs in Haiphong, Vietnam.
Des Jarlais DC; Thi Huong D; Thi Hai Oanh K; Khuê Pham M; Thi Giang H; Thi Tuyet Thanh N; Arasteh K; Feelemyer J; Hammett T; Peries M; Michel L; Vu Hai V; Roustide MJ; Moles JP; Laureillard D; Nagot N;
Int J Drug Policy; 2016 Jun; 32():50-6. PubMed ID: 27006257
[TBL] [Abstract][Full Text] [Related]
18. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada.
Enns EA; Zaric GS; Strike CJ; Jairam JA; Kolla G; Bayoumi AM
Addiction; 2016 Mar; 111(3):475-89. PubMed ID: 26616368
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique.
Semá Baltazar C; Horth R; Boothe M; Sathane I; Young P; Chitsondzo Langa D; Condula M; Ricardo H; Dengo Baloi L; Cummings B; Schaad N; Gouveia L; Teodoro E; Raymond HF
BMC Infect Dis; 2019 Dec; 19(1):1022. PubMed ID: 31791273
[TBL] [Abstract][Full Text] [Related]
20. Healthcare Access and Utilization Among Persons Who Inject Drugs in Medicaid Expansion and Nonexpansion States: 22 United States Cities, 2018.
Lewis R; Baugher AR; Finlayson T; Wejnert C; Sionean C;
J Infect Dis; 2020 Sep; 222(Suppl 5):S420-S428. PubMed ID: 32877551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
